-
Biotech Industry Intelligence3 weeks ago
Collegium is acquiring Corium’s approved ADHD drug for $650M
Collegium is acquiring Corium's approved ADHD drug for $650M
-
Uncategorized3 weeks agoMestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors...
-
Fierce Biotech3 weeks ago
Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure
Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely...
-
Uncategorized3 weeks ago
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
-
Biotech Industry Intelligence3 weeks ago
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win
Pfizer seeks earlier use of Talzenna in prostate cancer with Phase 3 win
-
Uncategorized3 weeks ago
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether...
-
AI & Machine Learning in Biotechnology3 weeks agoSTAT+: Eli Lilly’s ‘triple-G’ shows potency, raises concerns
Regulators are trying to push drug development into a post-animal testing era. Meanwhile, a Jennifer Doudna-founded company is edging toward successful CAR-T therapy done in vivo, and...
-
AI & Machine Learning in Biotechnology3 weeks agoSTAT+: A biotech turns to Apple Watch to study its Parkinson’s drug
You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life sciences. Sign up to get it delivered in your...
-
BioPharma Dive – AI / Data3 weeks agoA biotech VC sees early signs of a turnaround for startups
After a lengthy downturn, renewed optimism is building among young drugmakers and their backers as a new funding wave takes shape, said Santé Ventures’ Omar Khalil.
-
AI & Machine Learning in Biotechnology3 weeks agoDid we undercount Covid deaths by 155,000?
It’s Breakthrough Summit East day! If you weren’t able to snag a ticket to join us in New York City to hear from the leaders advancing...
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
